Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs

被引:9
作者
Hartgroves, L. C. S. [1 ]
Koudstaal, W. [2 ]
McLeod, C. [1 ]
Moncorge, O. [1 ]
Thompson, C. I. [3 ]
Ellis, J. [3 ]
Bull, C. [4 ]
Havenga, M. J. E. [5 ]
Goudsmit, J. [2 ]
Barclay, W. S. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Virol, Fac Med, London, England
[2] Crucell Holland BV, Leiden, Netherlands
[3] Ctr Infect, Hlth Protect Agcy, London, England
[4] Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England
[5] TNO Biosci, Leiden, Netherlands
关键词
Influenza; Reverse genetics; Vaccine; MDCK CELLS; REVERSE GENETICS; CLEAVAGE SITE; H5N1; VIRUSES; CHICKEN EGGS; HEMAGGLUTININ; NEURAMINIDASE; GROWTH; IMMUNOGENICITY; SELECTION;
D O I
10.1016/j.vaccine.2010.02.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Most influenza vaccines are produced in chicken eggs but recent human influenza strains often do not grow well in this substrate. The PER.C6 (R) cell line is an alternative platform for vaccine production. Here we demonstrate that PER.C6 cells faithfully propagate recent clinical isolates, without selecting for mutations in the HA gene. PER.C6 cells support the rescue of recombinant influenza viruses from cDNA. We used sequence data from a surveillance programme to generate a PR8-based seed virus with the HA and NA of a contemporary circulating H3N2 human strain, A/England/611/07 (E611) that did not itself grow in eggs. We engineered mutations that affected receptor-binding, G186V or L194P, into the E611 HA gene. Whilst the L194P mutation conferred efficient growth in eggs, G186V did not. The L194P mutation was also spontaneously selected during egg propagation of E611/PR8 7:1 recombinant virus. This suggests generation of a single recombinant vaccine seed might satisfy manufacturers that utilize either eggs or cells for vaccine production. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2973 / 2979
页数:7
相关论文
共 35 条
[31]   Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host [J].
Thompson, CI ;
Barclay, WS ;
Zambon, MC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (05) :759-765
[32]   Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans [J].
Treanor, JJ ;
Wilkinson, BE ;
Masseoud, F ;
Hu-Primmer, J ;
Battaglia, R ;
O'Brien, D ;
Wolff, M ;
Rabinovich, G ;
Blackwelder, W ;
Katz, JM .
VACCINE, 2001, 19 (13-14) :1732-1737
[33]   Functional balance between haemagglutinin and neuraminidase in influenza virus infections [J].
Wagner, R ;
Matrosovich, M ;
Klenk, HD .
REVIEWS IN MEDICAL VIROLOGY, 2002, 12 (03) :159-166
[34]   Expression and purification of an influenza hemagglutinin - one step closer to a recombinant protein-based influenza vaccine [J].
Wang, K ;
Holtz, KM ;
Anderson, K ;
Chubet, R ;
Mahmoud, W ;
Cox, MMJ .
VACCINE, 2006, 24 (12) :2176-2185
[35]  
WHITELEY A, 2007, RESP VIRUSES, V1, P157